Quantcast

Latest InterMune Inc. Stories

2014-09-05 08:23:44

BRISBANE, Calif., Sept. 5, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible Senior Notes Due 2015: Re: Notice of Anticipated Fundamental Change Reference is hereby made to the Indenture, dated as of June 24, 2008 (the "Indenture"), between InterMune, Inc., a Delaware corporation (the "Company" or "InterMune"), and The Bank of New York Mellon Trust Company, N.A., a...

2014-08-24 16:20:20

BOSTON, Aug. 24, 2014 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of InterMune, Inc. ("InterMune" or the "Company") (NASDAQ: ITMN) concerning its proposed merger with Roche in an all cash transaction. InterMune stockholders will receive $74 in cash for each InterMune share held. This represents a premium of...

2014-08-06 16:28:59

-- Transformational H1 2014 includes presentation of Phase 3 ASCEND data, NDA resubmission and target PDUFA date of Nov. 23 for pirfenidone in U.S. - BRISBANE, Calif., Aug. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter ended June 30, 2014. The company also highlighted recent clinical development and business highlights, and updated its forward-looking financial guidance for 2014. InterMune reported Esbriet(®)...

2014-07-28 08:29:20

BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets on Wednesday, August 6, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. Interested investors and others may participate in the conference call by dialing 800-728-2056 (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A...

2014-07-21 12:24:33

CHICAGO, July 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc....

2014-07-17 12:30:54

BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant...

2014-07-07 08:27:16

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 7, 2014 /PRNewswire/ -- On Thursday, July 03, 2014, the NASDAQ Composite ended at 4,485.93, up 0.63%, the Dow Jones Industrial Average advanced 0.54%, to finish the day at 17,068.26, and the S&P 500 closed at 1,985.44, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 721.38, up...

2014-05-27 08:27:56

BRISBANE, Calif., May 27, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). http://photos.prnewswire.com/prnvar/20120827/SF62570LOGO "We are pleased to have resubmitted the...

2014-05-20 16:27:10

- Pooled Efficacy Analyses from Phase 3 ASCEND and CAPACITY Studies Presented at 2014 American Thoracic Society Meeting - SAN DIEGO, May 20, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous Phase 3 CAPACITY trials evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were presented at the 2014 International Conference of the American Thoracic Society (ATS) in San Diego,...

2014-05-20 12:33:45

Editor Note: For more information about this release, please scroll to bottom LONDON, May 20, 2014 /PRNewswire/ -- The U.S. markets on Monday, May 19, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,511.86, up 0.12% and the NASDAQ Composite closed at 4,125.82, up 0.86%. The S&P 500 finished the session 0.38% higher at 1,885.08. During the trading session, seven out of ten sectors finished on a higher note. Investor-Edge looks at some of the...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related